On December 2020, the Therapeutic Goods Administration (TGA) announced that it will approve low-dose CBD containing products, up to a maximum consumption of 150 mg/day, for use by adults, to be supplied over the counter by a pharmacist, without a prescription. The TGA's final decision came into effect on 1 February 2021.
The decision was made following an earlier TGA safety review of low dose CBD - which revealed that the known adverse events of CBD at low doses were not severe. The decision was made following extensive public consultation.
The over-the-counter products will only be sold by way of oral, oral mucosal and sublingual formulations, with market estimation for consumers seeing medication on shelves likely pushed to late 2021/2022.